A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Obeldesivir (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OAKTREE
- Sponsors Gilead Sciences
Most Recent Events
- 09 Oct 2024 According to Gilead science media release, data from this study will be presented at IDWeek 2024, taking place from October 16-19.
- 06 Feb 2024 Primary endpoint (Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29) has not been met.
- 05 Feb 2024 Status changed from active, no longer recruiting to completed.